US FDA&39;s RealTime Oncology Review Times Coming Into Focus
US FDA's Real-Time Oncology Review Times Coming Into Focus
19:56 EDT 19 May 2019 |
SCRIP
With approval of AbbVie Inc./Genentech Inc.'s Venclexta as seventh under RTOR pilot, a roughly two-month median review time under the...
Original Article: US FDA's Real-Time Oncology Review Times Coming Into Focus
More From BioPortfolio on "US FDA's Real-Time Oncology Review Times Coming Into Focus"